BR112012021532B1 - Composição para tratamento de unhas com fungo - Google Patents
Composição para tratamento de unhas com fungo Download PDFInfo
- Publication number
- BR112012021532B1 BR112012021532B1 BR112012021532-9A BR112012021532A BR112012021532B1 BR 112012021532 B1 BR112012021532 B1 BR 112012021532B1 BR 112012021532 A BR112012021532 A BR 112012021532A BR 112012021532 B1 BR112012021532 B1 BR 112012021532B1
- Authority
- BR
- Brazil
- Prior art keywords
- nail
- weight
- fungus
- composition
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 163
- 238000011282 treatment Methods 0.000 title claims abstract description 160
- 230000002538 fungal effect Effects 0.000 title abstract description 10
- 241000233866 Fungi Species 0.000 claims abstract description 111
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 29
- 239000003906 humectant Substances 0.000 claims abstract description 27
- 239000002904 solvent Substances 0.000 claims abstract description 21
- 239000003112 inhibitor Substances 0.000 claims abstract description 12
- 239000003755 preservative agent Substances 0.000 claims abstract description 9
- 239000000975 dye Substances 0.000 claims abstract description 8
- 239000002304 perfume Substances 0.000 claims abstract description 8
- 239000000049 pigment Substances 0.000 claims abstract description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 22
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 18
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 11
- 239000004202 carbamide Substances 0.000 claims description 9
- 230000035515 penetration Effects 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- 239000000230 xanthan gum Substances 0.000 claims description 8
- 229940082509 xanthan gum Drugs 0.000 claims description 8
- 235000010493 xanthan gum Nutrition 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 7
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 229940101267 panthenol Drugs 0.000 claims description 6
- 235000020957 pantothenol Nutrition 0.000 claims description 6
- 239000011619 pantothenol Substances 0.000 claims description 6
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 4
- 239000004299 sodium benzoate Substances 0.000 claims description 4
- 235000010234 sodium benzoate Nutrition 0.000 claims description 4
- -1 sodium butyl phenol benzotriazolyl sulfonate Chemical compound 0.000 claims description 3
- 208000010195 Onychomycosis Diseases 0.000 abstract description 42
- 238000000034 method Methods 0.000 abstract description 16
- 239000003961 penetration enhancing agent Substances 0.000 abstract description 16
- 206010034016 Paronychia Diseases 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 210000000282 nail Anatomy 0.000 description 208
- 239000012530 fluid Substances 0.000 description 23
- 208000015181 infectious disease Diseases 0.000 description 18
- 241001480043 Arthrodermataceae Species 0.000 description 15
- 230000037304 dermatophytes Effects 0.000 description 15
- 206010017533 Fungal infection Diseases 0.000 description 12
- 208000031888 Mycoses Diseases 0.000 description 12
- 210000004906 toe nail Anatomy 0.000 description 12
- 230000000699 topical effect Effects 0.000 description 12
- 210000004905 finger nail Anatomy 0.000 description 11
- 210000004904 fingernail bed Anatomy 0.000 description 11
- 238000001804 debridement Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 229960003204 amorolfine Drugs 0.000 description 7
- MQHLMHIZUIDKOO-AYHJJNSGSA-N amorolfine Chemical group C1=CC(C(C)(C)CC)=CC=C1CC(C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-AYHJJNSGSA-N 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 201000005882 tinea unguium Diseases 0.000 description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- 241000223229 Trichophyton rubrum Species 0.000 description 5
- 229960001456 adenosine triphosphate Drugs 0.000 description 5
- 229940121375 antifungal agent Drugs 0.000 description 5
- 235000013877 carbamide Nutrition 0.000 description 5
- 239000003410 keratolytic agent Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000004922 lacquer Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 208000035415 Reinfection Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- HYTYHTSMCRDHIM-UHFFFAOYSA-M potassium;2-sulfanylacetate Chemical compound [K+].[O-]C(=O)CS HYTYHTSMCRDHIM-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000007163 Dermatomycoses Diseases 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010061304 Nail infection Diseases 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- YLYURHSBPLOMRT-UHFFFAOYSA-M sodium;2-hydroxypropane-1,2,3-tricarboxylic acid;benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1.OC(=O)CC(O)(C(O)=O)CC(O)=O YLYURHSBPLOMRT-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940126703 systemic medication Drugs 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
- A45D29/00—Manicuring or pedicuring implements
- A45D29/04—Nail files, e.g. manually operated
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
- A45D29/00—Manicuring or pedicuring implements
- A45D29/18—Manicure or pedicure sets, e.g. combinations without case, etui, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1003336.3 | 2010-02-26 | ||
| GB1003336A GB2478159A (en) | 2010-02-26 | 2010-02-26 | Composition for the treatment of fungal nail infection |
| PCT/GB2011/050379 WO2011104562A1 (en) | 2010-02-26 | 2011-02-25 | Fungal nail treatment composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112012021532A2 BR112012021532A2 (pt) | 2017-11-14 |
| BR112012021532B1 true BR112012021532B1 (pt) | 2019-07-02 |
Family
ID=42125744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012021532-9A BR112012021532B1 (pt) | 2010-02-26 | 2011-02-25 | Composição para tratamento de unhas com fungo |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2538938B1 (https=) |
| JP (1) | JP2013520483A (https=) |
| CN (1) | CN102844026A (https=) |
| AU (1) | AU2011219546B2 (https=) |
| BR (1) | BR112012021532B1 (https=) |
| ES (1) | ES2732892T3 (https=) |
| GB (1) | GB2478159A (https=) |
| PL (1) | PL2538938T3 (https=) |
| TW (1) | TW201138860A (https=) |
| WO (1) | WO2011104562A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3047664B1 (fr) * | 2016-02-15 | 2019-08-02 | Jean Robert Pascoualle | Principe actif apportant une solution therapeutique a des pathologies de l'ongle (onychomycoses,....et affilies), du lit ungueal, et des zones peripheriques |
| BE1025004B1 (nl) * | 2017-02-24 | 2018-09-24 | Oystershell Nv | Afpelbare nagellak |
| EP4552650A3 (en) * | 2017-11-21 | 2025-08-13 | Topix Pharmaceuticals, Inc. | Methods and compositions for treatment of skin |
| WO2020131147A1 (en) * | 2018-12-19 | 2020-06-25 | Marlinz Pharma, LLC | Topical compositions |
| CN113208937A (zh) * | 2020-01-21 | 2021-08-06 | 中国医学科学院北京协和医院 | 一种角质软化组合物及其制备方法和应用及治疗灰指甲的外用复方及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1003340A (en) | 1963-07-30 | 1965-09-02 | Automotive Prod Co Ltd | Improvements in and relating to diaphragm spring clutches |
| CN1040839C (zh) * | 1993-03-06 | 1998-11-25 | 青岛海洋大学 | 指甲露 |
| US20030235607A1 (en) * | 1998-02-13 | 2003-12-25 | Buck Carol J. | Compositions and methods for inhibiting fungal growth and transference |
| US6143794A (en) * | 1998-04-17 | 2000-11-07 | Bertek Pharmaceuticals, Inc. | Topical formulations for the treatment of nail fungal diseases |
| ES2260093T3 (es) * | 2000-01-03 | 2006-11-01 | Karl Kraemer | Preparados para la eliminacion ungueal atraumatica. |
| GB2358627A (en) * | 2000-01-28 | 2001-08-01 | Bon Bon Buddies Ltd | Dispenser for confectionery products |
| US6281239B1 (en) * | 2000-04-12 | 2001-08-28 | Bradley Pharmeaceuticals, Inc. | Method of treating onychomycosis |
| US6921529B2 (en) * | 2002-07-29 | 2005-07-26 | Joseph C. Maley | Treatment modality and method for fungal nail infection |
| US8486426B2 (en) * | 2002-07-29 | 2013-07-16 | Kimberly-Clark Worldwide, Inc. | Methods and compositions for treatment of dermal conditions |
| MXPA05002065A (es) * | 2002-09-05 | 2005-06-08 | Galderma Sa | Solucion para aplicacion ungueal. |
| FR2844197B1 (fr) * | 2002-09-05 | 2006-06-23 | Galderma Res & Dev | Solution pour application ungueale et peri-ungeale |
| US20050018199A1 (en) * | 2003-07-24 | 2005-01-27 | Leblanc Philip R. | Fiber array interferometer for inspecting glass sheets |
| AT414096B (de) * | 2005-05-03 | 2006-09-15 | Franz Kemptner | Antimykotikum |
| KR20090031726A (ko) * | 2006-06-14 | 2009-03-27 | 닥터 레디스 레보러터리즈 리미티드 | 국소용 조성물 |
| EP2526928B1 (en) * | 2007-02-05 | 2018-12-26 | Biophile Corporation, Ltd | Increased effectiveness of allylamine drug compounds |
| CN101099857A (zh) * | 2007-02-13 | 2008-01-09 | 贵州神奇集团控股有限公司 | 治疗脚手癣、灰指甲的中西复方制剂及其制备方法和质控方法 |
| FR2931683B1 (fr) * | 2008-06-02 | 2011-10-28 | Galderma Res & Dev | Dispositif d'application d'un produit de traitement sur une surface a traiter, utilisation d'un tel dispositif pour le traitement d'un ongle de pied ou de la main et kit de traitement correspondant. |
| EP2464334A4 (en) * | 2009-08-13 | 2014-03-26 | Moberg Derma Ab | COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTION OF NAILS |
-
2010
- 2010-02-26 GB GB1003336A patent/GB2478159A/en not_active Withdrawn
-
2011
- 2011-02-25 ES ES11706319T patent/ES2732892T3/es active Active
- 2011-02-25 WO PCT/GB2011/050379 patent/WO2011104562A1/en not_active Ceased
- 2011-02-25 AU AU2011219546A patent/AU2011219546B2/en active Active
- 2011-02-25 BR BR112012021532-9A patent/BR112012021532B1/pt not_active IP Right Cessation
- 2011-02-25 CN CN2011800112656A patent/CN102844026A/zh active Pending
- 2011-02-25 PL PL11706319T patent/PL2538938T3/pl unknown
- 2011-02-25 JP JP2012554425A patent/JP2013520483A/ja active Pending
- 2011-02-25 EP EP11706319.8A patent/EP2538938B1/en active Active
- 2011-03-01 TW TW100106635A patent/TW201138860A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2538938B1 (en) | 2019-04-24 |
| PL2538938T3 (pl) | 2019-09-30 |
| ES2732892T3 (es) | 2019-11-26 |
| TW201138860A (en) | 2011-11-16 |
| AU2011219546A1 (en) | 2012-09-13 |
| RU2012141024A (ru) | 2014-04-10 |
| BR112012021532A2 (pt) | 2017-11-14 |
| AU2011219546B2 (en) | 2016-01-14 |
| EP2538938A1 (en) | 2013-01-02 |
| GB201003336D0 (en) | 2010-04-14 |
| JP2013520483A (ja) | 2013-06-06 |
| CN102844026A (zh) | 2012-12-26 |
| GB2478159A (en) | 2011-08-31 |
| WO2011104562A1 (en) | 2011-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Angelo et al. | Chemical and physical strategies in onychomycosis topical treatment: A review | |
| Shanbhag et al. | Drug delivery through nails: Present and future | |
| RU2587041C2 (ru) | Способ предотвращения или лечения опухоли кожи | |
| Marty | Amorolfine nail lacquer: a novel formulation | |
| US20020102223A1 (en) | Antifungal composition and method for human nails | |
| MXPA05010114A (es) | Revestimiento anti-fungico para unas y metodo de uso. | |
| Barot et al. | Drug delivery to the nail: therapeutic options and challenges for onychomycosis | |
| BR112012021532B1 (pt) | Composição para tratamento de unhas com fungo | |
| US20050238672A1 (en) | Antifungal drug delivery | |
| US20090247580A1 (en) | Nitroxide radioprotector formulations and methods of use | |
| EP1931309B1 (en) | Antifungal composition | |
| Baker et al. | Progress on new therapeuties for fungal nail infections | |
| US20090192125A1 (en) | Local anti-infective agent for treatment of nail fungal infections | |
| CN101351189A (zh) | 用于治疗指（趾）甲病的药物组合物 | |
| Kiran et al. | Ungual drug delivery system of ketoconazole nail lacquer | |
| Muralidhar et al. | Transungual drug delivery: an over view | |
| Christi et al. | Review on transungual drug delivery system | |
| US20060280703A1 (en) | Antimycotic nail varnish | |
| RU2575774C2 (ru) | Композиция для лечения грибка ногтей | |
| US20140079804A1 (en) | Compositions and methods for treatment of infections | |
| US20180104227A1 (en) | Nail lacquer composition containing ciclopirox | |
| CA2495923A1 (en) | Methods for treating fungal infections | |
| CN112121033A (zh) | 用红外光和间苯二酚处理皮肤病症的组合物和方法 | |
| Yu et al. | Raybloc: A Marine Bioactive Silica-Microsponge Formulation Confers Superior Protection against Blue Light and Infrared-A Induced Skin Damage in Murine Model | |
| Shah et al. | CHALLENGES AND NOVEL APPROACHES FOR THE TREATMENT OF ONYCHOMYCOSIS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/02/2011, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/02/2011, OBSERVADAS AS CONDICOES LEGAIS |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 12A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2711 DE 20-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |